| No. |
Proposition |
|
For |
Against |
Abstain |
| 1 |
DIRECTOR Harel Gadot |
|
|
|
|
| 2 |
DIRECTOR Martin Madden |
|
|
|
|
| 3 |
DIRECTOR Tal Wenderow |
|
|
|
|
| 4 |
The approval of a non-binding advisory resolution supporting the compensation of the Companys named executive officers. |
|
|
|
|
| 5 |
The approval of a non-binding advisory resolution regarding the frequency of future non-binding advisory votes related to future named executive officer compensation. |
|
|
|
|
| 6 |
The issuance of Series I preferred investment options and placement agent options issued in connection therewith, and shares of common stock underlying such options, issued in connection with an offering and sale of securities of the Company that was consummated on February 11, 2025, for purposes of complying with Nasdaq listing rule 5635(d) and satisfying the Companys contractual obligations to the holders of such options. |
|
|
|
|
| 7 |
The approval of an amendment to the Companys Certificate of Incorporation, as amended and/or restated from time to time, to increase the total number of shares of common stock authorized for issuance. |
|
|
|
|
| 8 |
The approval of an amendment to the Microbot Medical Inc. 2020 Omnibus Performance Award Plan, to increase the number of authorized shares of common stock reserved for issuance by 2,591,019 shares. |
|
|
|
|
| 9 |
The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Companys independent registered public accounting firm for the year ending December 31, 2025. |
|
|
|
|